0001179110-22-001520.txt : 20220222 0001179110-22-001520.hdr.sgml : 20220222 20220222174252 ACCESSION NUMBER: 0001179110-22-001520 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220217 FILED AS OF DATE: 20220222 DATE AS OF CHANGE: 20220222 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Strom Carrie C CENTRAL INDEX KEY: 0001811896 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35565 FILM NUMBER: 22659632 MAIL ADDRESS: STREET 1: 1 N. WAUKEGAN ROAD CITY: NORTH CHICAGO STATE: IL ZIP: 60064 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: AbbVie Inc. CENTRAL INDEX KEY: 0001551152 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 320375147 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1 NORTH WAUKEGAN ROAD CITY: NORTH CHICAGO STATE: IL ZIP: 60064 BUSINESS PHONE: (847) 932-7900 MAIL ADDRESS: STREET 1: 1 NORTH WAUKEGAN ROAD CITY: NORTH CHICAGO STATE: IL ZIP: 60064 4 1 edgar.xml FORM 4 - X0306 4 2022-02-17 0 0001551152 AbbVie Inc. ABBV 0001811896 Strom Carrie C 1 N. WAUKEGAN ROAD NORTH CHICAGO IL 60064 0 1 0 0 SVP & Pres Global Allerg Aesth Common Stock, $0.01 par value 2022-02-17 4 A 0 5727 0 A 48226 D Option(Right to Buy) 144.54 2022-02-17 4 A 0 24080 0 A 2023-02-17 2032-02-16 Common Stock 24080 24080 D Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 18, 2021. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2022. Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 8,027 on February 17, 2023, 8,027 on February 17, 2024, and 8,026 on February 17, 2025. Steven L. Scrogham, attorney-in-fact for Carrie Strom 2022-02-22